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Abstract
Objective: We aimed to investigate mutation-specific white matter (WM)
integrity changes in presymptomatic and symptomatic mutation carriers of the
C9orf72, MAPT, and GRN mutations by use of diffusion-weighted imaging
within the Genetic Frontotemporal dementia Initiative (GENFI) study.
Methods: One hundred and forty mutation carriers (54 C9orf72, 30 MAPT, 56
GRN), 104 presymptomatic and 36 symptomatic, and 115 noncarriers under-
went 3T diffusion tensor imaging. Linear mixed effects models were used to
examine the association between diffusion parameters and years from estimated
symptom onset in C9orf72, MAPT, and GRN mutation carriers versus noncarri-
ers. Post hoc analyses were performed on presymptomatic mutation carriers
only, as well as left–right asymmetry analyses on GRN mutation carriers versus
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noncarriers. Results: Diffusion changes in C9orf72 mutation carriers are present
significantly earlier than both MAPT and GRN mutation carriers – characteristi-
cally in the posterior thalamic radiation and more posteriorly located tracts
(e.g., splenium of the corpus callosum, posterior corona radiata), as early as
30 years before estimated symptom onset. MAPT mutation carriers showed
early involvement of the uncinate fasciculus and cingulum, sparing the internal
capsule, whereas involvement of the anterior and posterior internal capsule was
found in GRN. Restricting analyses to presymptomatic mutation carriers only,
similar – albeit less extensive – patterns were found: posteriorly located WM
tracts (e.g., posterior thalamic radiation, splenium of the corpus callosum, pos-
terior corona radiata) in presymptomatic C9orf72, the uncinate fasciculus in
presymptomatic MAPT, and the internal capsule (anterior and posterior limbs)
in presymptomatic GRN mutation carriers. In GRN, most tracts showed signifi-
cant left–right differences in one or more diffusion parameter, with the most
consistent results being found in the UF, EC, RPIC, and ALIC. Interpretation:
This study demonstrates the presence of early and widespread WM integrity
loss in presymptomatic FTD, and suggests a clear genotypic “fingerprint.” Our
findings corroborate the notion of FTD as a network-based disease, where
changes in connectivity are some of the earliest detectable features, and identify
diffusion tensor imaging as a potential neuroimaging biomarker for disease-
tracking and -staging in presymptomatic to early-stage familial FTD.
Introduction
Genetic FTD with an autosomal dominant inheritance
pattern has a heterogeneous clinical profile, including
behavioral variant FTD (bvFTD) and primary progressive
aphasia (PPA). The Chromosome 9 open reading frame 72
(C9orf72) repeat expansion, and mutations in the micro-
tubule-associated protein tau (MAPT) and progranulin
(GRN) genes are the three most common causes of famil-
ial FTD.1–3 At-risk subjects within the presymptomatic
stage allow a unique time-window into the earliest disease
stages of FTD, important for diagnostic improvement and
the development of robust and sensitive biomarkers.4,5
The Genetic Frontotemporal dementia Initiative (GENFI)
is a longitudinal cohort study of familial FTD across Eur-
ope and Canada, investigating carriers of the C9orf72,
MAPT, or GRN mutations and their healthy first-degree
relatives. Cross-sectional analyses on volumetric MR
images in GENFI demonstrated frontotemporal gray mat-
ter (GM) volume loss from 10 years before estimated
symptom onset, confirming that the disease process pre-
cedes the clinical onset by several years in familial FTD.6
White matter (WM) alterations, as measured by diffu-
sion tensor imaging (DTI) are found to be early and
widespread in the symptomatic phase of FTD, extending
beyond the zones of GM atrophy,7–9 with distinct profiles
in clinical and genetic subtypes.7,10–14 The pattern of WM
integrity loss includes the uncinate fasciculus (UF), cingu-
lum, (anterior) corpus callosum, fornix, superior and
inferior longitudinal fasciculi, thalamic radiation, and
corona radiata.7,12,14–16 Also, previous studies in presymp-
tomatic FTD caused by GRN and MAPT mutations
demonstrated, respectively, lower integrity of the UF,17,18
and inferior frontooccipital fasciculus,17 whereas studies
into presymptomatic C9orf72 have shown more inconsis-
tent results.19–21 This underlines that, although a promis-
ing candidate, larger studies are needed in order to
validate DTI as a neuroimaging biomarker for presymp-
tomatic FTD.
In this study, we compared baseline DTI parameters
between mutation carriers and noncarriers in families
with autosomal dominant FTD caused by C9orf72, MAPT,
and GRN mutations within the GENFI consortium.6 We
hypothesized that the three different pathogenic groups
have distinct profiles, with increasing WM integrity loss
when moving from the presymptomatic to early symp-
tomatic stage.
Methods
Participants
Within the second GENFI data freeze,6 365 participants
from genetically confirmed FTD families with either a
C9orf72 repeat expansion, MAPT, or GRN pathogenic
mutation were recruited from 13 research centers between
January 30, 2012 and May 4, 2015. Six participants did
not have MR imaging performed, and were therefore
excluded. To improve data homogeneity, we excluded
images from 1.5T scanners (n = 50). All images were
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subjected to strict visual quality control, which led to 54
participants being excluded from further analysis, mainly
due to motion and artifacts. The final sample consisted of
255 subjects, of which 140 were mutation carriers (54
C9orf72, 30 MAPT, 56 GRN) and 115 were non-carriers
(see Fig. 1 for the sample flowchart).
Standard protocol approvals, registrations,
and patient consents
Written informed consent was obtained from all partici-
pants at study enrolment. The study was approved by the
local Medical and Ethical Review committees at each
research site. DNA genotyping was performed locally at
each research site. We defined a pathogenic repeat expan-
sion in C9orf72 as more than 30 repeats.22 If presymp-
tomatic participants had not undergone predictive testing,
the clinical investigators were blinded to their genetic
status.
Clinical assessment
All participants underwent a standardized clinical assess-
ment consisting of a medical and family history, neuro-
logical examination, neuropsychological testing, and MR
imaging of the brain. We determined clinical status
according to established diagnostic criteria,23,24 based on
this assessment and information from a structured inter-
view with knowledgeable informants. The interview con-
sisted of questions regarding behavioral, neuropsychiatric,
cognitive, (instrumental) activities of daily living, motor,
and autonomic symptoms. Furthermore, we quantitatively
measured functional and/or behavioral changes by means
of the Cambridge Behavioural Inventory Revised (CBI-
R).25 Global cognition was assessed by means of the
Mini-Mental State Examination (MMSE).26
DTI acquisition and (pre)processing
We performed 3T diffusion-weighted and volumetric T1-
weighted MRI. Scanning was performed on MRI scanners
from five vendors, see Data S2 for an overview of the
number of participants and research sites per vendor, and
scan parameters. In case diffusion-weighted images con-
sisted of multiple acquisitions, NifTI files were merged
within the FMRIB Software Library (FSL, v5.0.4)27; bvec
and bval files were concatenated within MATLAB
(v2012a). Diffusion-weighted images were then prepro-
cessed and analyzed using a combination of tools from
DTI-TK (http://dti-tk.sourceforge.net) and NiftyPipe
(http://cmictig.cs.ucl.ac.uk/wiki/index.php/NiftyPipe) soft-
ware packages.28 In short, diffusion images were corrected
for motion and eddy-current via an affine coregistration
between the diffusion-weighted image to the average b0
image. Images were also corrected for susceptibility via
phase unwrapping.29 Diffusion tensor volumes were spa-
tially normalized to a population-specific tensor template
with DTI-TK.30,31 The structural T1-weighted image was
used for reference space. To restrict analyses to brain
matter and improve registration, we applied a subject
specific binary T1 brain mask image, created by means of
the Neuromorphometrics protocol.32,33 We extracted dif-
fusion parameters (fractional anisotropy [FA], mean
[MD], radial [DR], and axial diffusivity [AxD]) in WM
Figure 1. Overview of participant in- and exclusion. A total of 365 subjects were eligible for study participation. Six subjects did not undergo MRI
scanning, and were therefore excluded. Only 3T scans were considered; therefore, 1.5T (n = 34) scans were first excluded from further analysis.
Visual quality control of the images resulted in exclusion of another 54 images, leading to a final dataset of 255 subjects (115 noncarriers (“nc”),
104 presymptomatic mutation carriers, 36 symptomatic carriers.
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regions-of-interest (ROI) from the John Hopkins Univer-
sity (JHU) atlas34 using FSL,27 and selected the following
tracts: uncinate fasciculus (UF); superior longitudinal fas-
ciculus (SLF); cingulum, sagittal stratum; posterior thala-
mic radiation (PTR); anterior (ACR), posterior (PCR),
and superior (SCR) corona radiata; external capsule (EC);
anterior (ALIC), and posterior limb (PLIC); and retrolen-
ticular part (RPIC) of the internal capsule; and genu,
body, and splenium of the corpus callosum (respectively,
gCC, bCC, and sCC). Left and right values were averaged
to obtain one value per tract.
Statistical analysis
Data analysis was carried out using STATA (version 14.2;
College Station, TX: StataCorp LP), with the significance
level set at P < 0.05 (two-tailed) across all comparisons.
Each participant’s age at baseline was subtracted from the
average age at onset of symptoms in their family to estimate
the years to estimated symptom onset (EYO).6 EYO, and
not actual onset age, was also used in symptomatic muta-
tion carriers in order to provide a common time scale for
the analysis. Age at baseline, estimated age at symptom
onset, years from estimated symptom onset, and years of
education were compared between groups by means of lin-
ear regression analyses. Logistic regression was used to
investigate differences in sex, and scores on the CBI-R and
MMSE. Robust standard errors were used to account for
clustering by family. We used linear mixed effects models
to examine whether the association between diffusion
parameters and EYO differed between each mutation car-
rier group (C9orf72, MAPT, and GRN) and noncarriers. A
random intercept for family was included, allowing diffu-
sion parameters to be correlated between members of the
same family rather than assuming independence. All analy-
ses were adjusted for sex and research site. To allow for
nonlinear change in each diffusion parameter, we used a
restricted cubic spline35 for EYO. The spline terms for EYO
were included as predictors in the model, along with the
interactions between each spline term for EYO and indica-
tor variables for mutation carrier group (C9orf72, MAPT,
and GRN). The spline modeling approach was chosen to
allow a complex pattern of association with EYO, for exam-
ple, FA might increase and then later on become lower. The
knots were placed at -20, 5, and +7 years relative to
expected onset to ensure that each group had a least five
participants before the last knot point and after the final
knot point, with the middle point splitting the remaining
participants into groups of approximately equal sizes. Post
hoc, we reran the abovementioned analyses in presymp-
tomatic mutation carriers only (with knots at 20, 10,
and 0 EYO). We also investigated left–right differences in
GRN by calculating the asymmetry in each WM tract as
absolute difference in diffusion parameter (left–right)/
mean diffusion parameter. As asymmetry values were
skewed, we modeled them as a natural log (ln(Asymmetry)
– but for easier interpretation, we presented the results after
exponentiation giving geometric means and ratios of geo-
metric means between groups. As with previous analyses,
we used a mixed effect model allowing for clustering by
family and with spline terms for years to estimated symp-
tom onset (knots at 20, 5, and +7 EYO).
For each model, we conducted a hypothesis test of
whether the mean value of the diffusion parameter differed
between each mutation carrier group (C9orf72, MAPT, and
GRN) compared to noncarriers. This was a joint Wald test
of the indicator variable for the mutation carrier group of
interest and its interactions with the spline terms for EYO.
Therefore, for the primary analysis, 60 tests were conducted
to compare each mutation carrier group to noncarriers (15
tracts * 4 diffusion parameters). No formal correction was
made for multiple comparisons, as diffusion measures were
not independent. From each model, we also predicted the
mean value of the diffusion parameter for each group, and
the differences between each mutation carrier group and
noncarriers every year between 30 years before estimated
onset and 10 years after estimated onset. We conducted a
sensitivity analysis to examine the impact of outliers on the
findings on association between diffusion parameters and
EYO. The linear mixed effects model described above was
repeated for each diffusion parameter in each tract after
excluding any participants with model residuals more than
three standard deviations away from the predicted mean in
the initial analysis.
Results
Demographic and clinical data
Demographic and clinical data are shown in Table 1.
DNA genotyping assigned participants either to the muta-
tion carrier (n = 140; 54 from C9orf72 families, 30 from
MAPT families, and 56 from GRN families) or noncarrier
(n = 115; 37 C9orf72, 14 MAPT, 64 GRN) group. Hun-
dred and four participants were presymptomatic (17
MAPT, 52 GRN, 35 C9orf72), and 36 were symptomatic
(19 C9orf72, 13 MAPT, 4 GRN). The estimated age at
onset was lower in MAPT mutation carriers than both
GRN and C9orf72 mutation carriers (both P < 0.001). All
three mutation carrier groups had significantly lower
MMSE scores than noncarriers (C9orf72 P < 0.001, GRN
P = 0.006, MAPT P = 0.004). CBI-R scores were signifi-
cantly higher in MAPT and C9orf72 mutation carriers
compared to noncarriers (both P < 0.001), and compared
to GRN mutation carriers (MAPT P = 0.002, C9orf72
P = 0.003). There were no significant differences regarding
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sex, age, years from estimated symptom onset, or educa-
tion. Table 2 provides an overview of the distribution of
symptomatic and presymptomatic mutation carriers and
noncarriers across EYO. There was one mutation carrier
(C9orf72) who became symptomatic before their estimated
onset age (between 10 and 5 EYO). Nineteen presymp-
tomatic mutation carriers (4 C9orf72, 3 MAPT, 12 GRN)
were past their estimated onset age.
C9orf72 mutation carriers
Analyses of all symptomatic and presymptomatic C9orf72
repeat expansion carriers demonstrated significant
presymptomatic differences across all WM tracts and dif-
fusion metrics (Table 3, Fig. 2A). The earliest presymp-
tomatic changes – between 30 and 20 years before
estimated onset – were seen in the PTR, PCR, RPIC, sCC,
and gCC, followed by the UF and cingulum. In the last
decade prior to estimated onset, significant differences
were also found in the bCC, PLIC, EC, SCR, sagittal stra-
tum, and SLF. Surprisingly, in the ALIC, the diffusivity
values in repeat expansion carriers became more similar to
those of noncarriers, and did not differ significantly dur-
ing an intermediate period from respectively 20–10 years
before estimated symptom onset. See Data S3 for means,
mean differences, and P-values per year before estimated
onset. Post hoc analyses on only presymptomatic expan-
sion carriers demonstrated similar – albeit less extensive –
patterns of WM integrity loss, with the earliest and most
consistent differences found in the posterior WM tracts,
for example, PTR, sCC, PCR (Data S4A). In the late
presymptomatic stage the internal capsule (RPIC, ALIC,
PLIC) also became involved (Data S4A).
MAPT mutation carriers
Analyses of all symptomatic and presymptomatic MAPT
mutation carriers had significant differences from noncar-
riers across several WM tracts (Table 3, Fig. 2B). There
was very early involvement of the UF: higher diffusivity
was found between 30 and 20 years before estimated
symptom onset, and again from 3 years before estimated
Table 1. Demographic and clinical data.
Mutation carriers (n = 140) Noncarriers (n = 115) P-value
Female 75 (53.6) 73 (63.5) 0.100
Age (years) 50.1  12.9 49.4  13.3 0.682
Mutated gene
C9orf72 54 (38.6) 37 (32.3) –
MAPT 30 (21.4) 14 (12.2) –
GRN 56 (40.0) 64 (55.7) –
Clinical status
Presymptomatic 104 (74.3) 115 (100) –
Symptomatic 36 (25.7) 0 (0) –
Estimated age at onset 57.2  6.5 59.3  7.1 0.066
Years from estimated onset 7.1  12.6 9.9  14.4 0.193
Education (years) 13.8  3.2 14.0  3.2 0.637
MMSE 28.1  2.8 29.3  1.0 <0.001
CBI-R 19.7  33.0 3.1  5.4 <0.001
Mutation carriers C9orf72 MAPT GRN P-value1
Female 27 (50) 14 (46.7) 34 (60.7) 0.254
Age 50.6  14.0 47.4  12.7 51.0  11.8 0.549
Clinical status
Presymptomatic 35 (33.7) 17 (16.3) 52 (50) –
Symptomatic 19 (52.8) 13 (36.1) 4 (11.1) –
Estimated age at onset 58.3  6.9 51.0  6.0 59.5  3.9 <0.001
Years from estimated onset 7.7  13.7 3.6  12.0 8.5  11.6 0.244
Education (years) 14.0  3.1 13.0  4.0 14.2  2.9 0.668
MMSE 27.8  2.9 27.8  3.7 28.6  2.0 <0.001
CBI-R 26.3  36.5 33.2  40.0 6.1  16.8 <0.001
Values indicate: count (percentage) or mean  standard deviation.
C9orf72, chromosome 9 open reading frame 72; MAPT, microtubule-associated protein tau; GRN, progranulin; MMSE, Mini-Mental State Exami-
nation; CBI-R, Cambridge Behavioural Inventory – Revised.
1Represents overall P-value for comparison of noncarriers, C9orf72, MAPT, and GRN mutation carriers.
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symptom onset. Somewhat inconsistent findings were
demonstrated for the SLF, cingulum, and SCR: all three
tracts had a presymptomatic time-window in which FA
was increased, while diffusivity values were decreased.
After estimated symptom onset, mutation carriers also
had changes in the PCR, ACR, sagittal stratum, PTR, EC,
and corpus callosum (gCC, bCC, and sCC). There was
weaker evidence for differences in the RPIC, PLIC, and
ALIC, and even 10 years postonset values did not show
consistent differences compared with noncarriers. See
Data S3 for means, mean differences, and P-values per
year before estimated onset. Post hoc analyses on
presymptomatic mutation carriers only confirm the early
involvement of the UF: AxD changes are found between
30 and 24 years before estimated symptom onset, fol-
lowed by changes in FA, MD, and RD shortly before or
around estimated symptom onset (Data S4B). Further-
more, early presymptomatic changes were also found in
the cingulum, SLF, and SCR. After estimated symptom
onset, the internal capsule (ALIC and PLIC) also demon-
strated diffusivity changes (Data S4B).
GRN mutation carriers
Analyses of all symptomatic and presymptomatic GRN
mutation carriers had significant differences from noncar-
riers across a relatively limited number of WM tracts
(Table 3, Fig 2C). The strongest evidence for differences
were in the PLIC, ALIC, PCR, SCR, sCC, SLF, and cingu-
lum. The most consistent presymptomatic WM integrity
changes were in the ALIC and PLIC, which showed sig-
nificant differences from noncarriers from 10 years before
estimated onset. Early presymptomatic changes were also
found in the sCC, but differences only remained signifi-
cant up to 4 years postonset. The SLF and SCR showed
differences from 1 to 2 years before estimated onset, fol-
lowed by the cingulum and PCR only after estimated
onset. The overall test comparing GRN mutation carriers
to noncarriers did not show evidence for WM integrity
changes in UF, sagittal stratum, PTR, ACR, RPIC, bCC,
and gCC. It was particularly notable that even 10 years
after estimated onset, the diffusivity values of the sagittal
stratum, RPIC, ACR, and PTR were not significantly dif-
ferent between mutation carriers and noncarriers. See
Data S3 for means, mean differences, and P-values per
year before estimated onset. Post hoc analyses on only
presymptomatic mutation carriers showed consistent dif-
fusivity changes in the internal capsule (ALIC and PLIC)
alone (Data S4C).
We additionally investigated left–right differences
between GRN mutation carriers and noncarriers. In most
tracts significant left–right differences were found between
groups in one or more diffusion parameters (Data S5).
The most consistent results were found in the UF, EC,
RPIC, and ALIC (Data S5). Asymmetry in the UF was
mostly present in the early presymptomatic stage (30 to
+1 EYO), while the EC, RPIC, and ALIC demonstrated
asymmetry across the entire EYO range for different dif-
fusion parameters (Data S6). Interestingly, the four tracts
demonstrated different patterns over time (Data S6). The
UF showed less asymmetry with disease progression, while
a sharp postonset increase was seen for the ALIC. In the
EC a U-shape pattern was visible, with first a decrease in
asymmetry in the early presymptomatic stage, followed by
an increase from around 5 EYO. The RPIC demon-
strated an inverse U-shape, with first more asymmetry in
Table 2. Distribution of C9orf72, GRN, and MAPT symptomatic mutation carriers, presymptomatic mutation carriers, and noncarriers across esti-
mated years to onset.
Mutation
EYO
<25 25 to 20 20 to 15 15 to 10 10 to 5 5 to 0 0 to +5 +5 to +10 +10
C9orf72
Symptomatic 0 0 0 0 1 0 5 11 2
Presymptomatic 6 4 8 8 2 3 1 2 1
Noncarriers 7 4 4 5 4 4 2 4 3
MAPT
Symptomatic 0 0 0 0 0 0 4 7 2
Presymptomatic 1 3 4 2 3 1 2 1 0
Noncarriers 0 1 2 4 2 0 1 2 2
GRN
Symptomatic 0 0 0 0 0 0 4 0 0
Presymptomatic 6 4 5 7 9 9 4 8 0
Noncarriers 10 5 8 1 9 12 12 5 2
EYO, estimated years to symptom onset; C9orf72, chromosome 9 open reading frame 72; MAPT, microtubule-associated protein tau; GRN,
progranulin.
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the early presymptomatic stage, followed by a decrease
from around 5 EYO.
Sensitivity analysis
The number of outliers that were excluded for the sensi-
tivity analysis depended on the tract and DTI parameter,
with a maximum of five outliers. Findings were compara-
ble once these outliers were excluded. For the C9orf72
mutation carriers significant differences with noncarriers
were apparent in all WM tracts. These differences
remained apparent up to 30 years before estimated symp-
tom onset. In MAPT mutation carriers there remained
differences in the WM tracts that were previously identi-
fied and the same pattern remained with early involve-
ment of the UF. For GRN mutation carriers consistent
differences were still detected in the same WM tracts with
the earliest differences seen in the ALIC and PLIC.
Discussion
This study describes WM integrity changes by means of
DTI in mutation carriers and noncarriers from families
with autosomal dominant FTD due to mutations in
C9orf72, MAPT, and GRN, within the GENFI consortium.
Early WM involvement was found in mutation carriers,
with specific genetic patterns for the C9orf72, MAPT, and
GRN mutations. Our study suggests spreading WM integ-
rity loss toward symptom onset, highlighting the value of
DTI as disease-tracking and -staging biomarker in familial
FTD.
Table 3. P-values for difference in diffusion parameters between
mutation carriers and noncarriers.
Table 3. Continued.
Colors indicate statistical significance, ranging from white (nonsignifi-
cant) to red (significant P ≤ 0.001).
C9orf72, chromosome 9 open reading frame 72; MAPT, microtubule-
associated protein tau; GRN, progranulin; UF, uncinate fasciculus; SLF,
superior longitudinal fasciculus; PTR, posterior thalamic radiation; PCR,
posterior corona radiata; SCR, superior corona radiata; ACR, anterior
corona radiata; EC, external capsule, RPIC, retrolenticular part of the
internal capsule; PLIC, posterior limb of the internal capsule; ALIC,
anterior limb of the internal capsule; sCC, splenium of the corpus cal-
losum; bCC, body of the corpus callosum; gCC, genu of the corpus
callosum.
(Continued)
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The pattern of WM integrity changes in the early
presymptomatic stage shows large resemblance to the
regions known to be affected in both familial7,12,15,16 and
sporadic11,36–39 symptomatic FTD. Furthermore, although
the cohort was somewhat different, the damage to the
WM seems to be earlier and more widespread than the
GM volume loss found earlier in GENFI,6 a finding con-
sistent with previous work in presymptomatic familial17,18
and sporadic FTD.11,36–39 More WM tracts appear to be
involved in this study compared to previous studies of
presymptomatic familial FTD.17–21 An explanation for this
more extensive involvement may be sought in our larger
sample size (more power to detect small differences, and
covering a broader presymptomatic period) and the use
of all four diffusion parameters, compared to FA only in
previous studies. The additional three diffusivity parame-
ters appeared to be more sensitive than FA, and may pro-
vide more accurate measures of the effect and extent of
the WM integrity changes in the presymptomatic phase.
The most interesting findings are the gene-specific “fin-
gerprints” of WM integrity loss in C9orf72, MAPT, and
GRN mutation carriers. Restricting our analyses to
presymptomatic mutation carriers confirmed these find-
ings. In C9orf72, specifically the more posteriorly located
tracts, such as the PTR, PCR, and sCC, are affected. The
PTR demonstrates the earliest changes already 30 years
before estimated onset – suggesting that damage might be
present even before that. This is in line with earlier find-
ings in the GENFI cohort showing GM volume loss of
the thalamus and posterior cortical areas from 25 years
before estimated onset.6 The similar pattern and timing
of WM pathology seems consistent with the long-standing
and slowly progressive symptomatic changes often seen in
this mutation,40,41 and coherent with the hypothesis of a
developmental origin in C9orf72-associated FTD.6 In both
MAPT and GRN, WM changes have been consistently
found later than in C9orf72. The observation of presymp-
tomatic changes in the UF and cingulum in MAPT muta-
tion carriers is consistent with smaller series of
presymptomatic18 and symptomatic carriers,7,42 and con-
gruent with tracts affected in bvFTD, the most common
clinical phenotype of MAPT.43 We could not confirm
greater WM damage in the SLF in symptomatic cases
with underlying FTD-tau than FTD-TDP (e.g., GRN or
C9orf72) found in a previous study,14 suggesting that this
difference might occur later in the disease process or
resembles a phenotypic rather than genotypic origin.13,14
We could not explain the remarkable finding of DTI
changes into the opposite direction in the SLF, SCR, cin-
gulum between 30 and 16 years before EYO, and lar-
ger samples and follow-up data (longitudinal changes
within an individual) are needed to investigate whether
the pattern is of pathophysiological or methodological
nature. Recent literature provides evidence of WM
involvement in GRN-related FTD,44,45 though on the con-
trary in our GRN mutation carriers few tracts were
affected, and integrity loss was generally closer to esti-
mated symptom onset than early presymptomatic. Previ-
ous studies demonstrated lower FA in the UF of
presymptomatic GRN mutation carriers,17,18 and we did
find lower FA in the presymptomatic period, but no dif-
ferences in the symptomatic stage or in other diffusion
parameters. One potential explanation for this discrep-
ancy could be the large variation in age at onset within
GRN families,46 making the estimated age at onset less
reliable than in the other mutations. Another point for
consideration here is the potential masking of effects by
taking the mean value per WM tract, given the asymmet-
ric neuroimaging phenotype of GRN.47
Left–right asymmetry was present in most WM tracts
of GRN mutation carriers, with the most consistent asym-
metry being found in the UF, EC, RPIC, and ALIC. These
results not only demonstrate that some tracts are more
vulnerable to disproportionate WM integrity loss than
others (e.g., no asymmetry in the corona radiata), but
also that the development of asymmetry has a different
timing and pattern in various WM tracts. In line with
previous neuroimaging research, showing more asymme-
try with disease progression in symptomatic GRN muta-
tion carriers,48 we found a sharp increase in asymmetry
after estimated symptom onset in the ALIC, whereas the
inverse was seen in the UF. Rohrer et al.6 found greater
whole brain GM asymmetry in presymptomatic GRN
mutation carriers starting 5 years before estimated symp-
tom onset. Also in our study the 5 EYO seems to be a
critical time point in the development of WM asymmetry,
Figure 2. Gene-specific differences in WM integrity between mutation carriers and noncarriers between minus 30 years before estimated onset until
10 years postestimated onset. Schematic overview of mean diffusion differences between noncarriers and C9orf72 (A), MAPT (B) and GRN mutation
carriers (C) between minus 30 years before estimated symptom onset and plus 10 years after estimated onset (x-axis), each row represents a different
WM tract (y-axis). Blue = where the difference between mutation carriers and noncarriers is negative; green = where the difference between mutation
carriers and noncarriers is positive. NB: for FA, blue represents lower FA (=lower WM integrity) in mutation carriers than in noncarriers; for MD, RD, and
AxD, green represents higher parameters (=lower WM integrity) in mutation carriers than in noncarriers. UF, uncinate fasciculus; SLF, superior
longitudinal fasciculus; Sag.Stra., sagittal stratum; PTR, posterior thalamic radiation; PCR, posterior corona radiata; SCR, superior corona radiata; ACR,
anterior corona radiata; EC, external capsule; RPIC, retrolenticular part of the internal capsule; PLIC, posterior limb of the internal capsule; ALIC, anterior
limb of the internal capsule; sCC, splenium of the corpus callosum; bCC, body of the corpus callosum; gCC, genu of the corpus callosum.
ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 9
L. C. Jiskoot et al. DTI in Presymptomatic Familial FTD
with the EC demonstrating more asymmetry and the
RPIC showing less asymmetry after 5 EYO. More
research using longitudinal data is needed to investigate
the development of asymmetry over time in more detail.
The development of sensitive biomarkers for diagnosis,
for example, differentiation between clinical, genetic, or
pathological subtypes, and staging purposes is one of the
main challenges in presymptomatic FTD, as future thera-
peutic interventions ideally start in the unique time-win-
dow of minimal pathological damage. Although the
identification of “upstream” biomarkers is essential for the
development of therapeutic trials, the connectivity corre-
lates of FTD pathophysiological processes were thus far
unknown for the presymptomatic stage.13 Our results
demonstrate the potential application of DTI as a future
diagnostic and staging biomarker – providing evidence of
very early presymptomatic alterations as well as consistent
WM integrity loss when moving from the late presymp-
tomatic into the early symptomatic stage. Also, mutation-
specific profiles for C9orf72, MAPT, and GRN suggest the
potential of DTI in pathology-specific clinical trials. In
contrast to FA reductions as a measure of WM integrity
loss in previous studies,49 diffusivity measures (MD, RD,
AxD) reflected early WM alterations much more sensi-
tively. This is consistent with a previous study into the
clinical subtypes of FTD,50 supporting the notion that FA
does not capture the full extent of WM pathology, and the
four metrics signify different underlying processes with
disease progression. As a next step, postmortem studies are
needed to increase our understanding of the histopatho-
logical representation of WM changes in relationship with
markers of demyelination, neuroinflammation, neuronal
loss, and underlying pathology. Furthermore, to use DTI
in clinical practice, more research is needed on the transla-
tion of our group-based results to the individual patient
level. Larger studies are also needed to differentiate patho-
logical subtypes in individual patients.51 Lastly, as neurofil-
ament light chain is thought to be a sensitive marker of
axonal damage, and therefore could be associated with
DTI,52 it would be interesting to investigate this biomarker
further in this cohort.
Key strengths of our study constitute the large sample of
FTD mutation carriers and noncarriers. Our study
describes the presymptomatic to early symptomatic stage
of familial FTD in a long time trajectory of 40 years, with
only a single symptomatic mutation carrier (C9orf72)
before their estimated onset age. Therefore, the influence of
this symptomatic mutation carrier is most likely very mini-
mal. With respect to preprocessing, registration was
improved by computing the image similarity on the basis
of full tensor images rather than scalar features, in which
the algorithm incorporates local fiber orientations as fea-
tures driving the alignment of individual WM tracts. The
use of only 3T images, extensive data control after each
preprocessing step, and our sensitivity analysis further
ascertained data homogeneity. In the pilot phase of GENFI,
more variable DTI acquisition parameters and protocols
(e.g., use of field and phase maps) were used, introducing a
source of bias to the data. Now in the second phase of
GENFI, scan protocols have been fully harmonized, so that
from 2015 onwards we are building on a much more con-
sistent dataset. Exploring the involvement of corticospinal
tracts, as recent research demonstrated early damage in
C9orf72-associated ALS,19 bvFTD, and PPA,50 would be a
very informative next step. Other future directions include
the investigation of DTI as a longitudinal neuroimaging
biomarker and its potential role in multimodal and com-
posite scores in presymptomatic FTD.
Our study provides evidence of global and gene-specific
WM integrity loss as an early pathological feature of
presymptomatic familial FTD, making DTI a promising
diagnostic and staging neuroimaging biomarker that in
the future could be used in upcoming clinical trials for
familial FTD.
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